MCID: URT035
MIFTS: 32

Urethral Benign Neoplasm malady

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Urethral Benign Neoplasm

Aliases & Descriptions for Urethral Benign Neoplasm:

Name: Urethral Benign Neoplasm 12
Urethral Neoplasms 42 69
Urethra Cancer 12 14
Malignant Neoplasm of Urethra 69
Malignant Tumour of Urethra 12
Malignant Urethral Neoplasm 12
Neoplasm of Urethra 12
Urethral Carcinoma 69
Neoplasm. Urethra 12
Cancer of Urethra 12
Urethral Ca 12

Classifications:



External Ids:

Disease Ontology 12 DOID:730 DOID:734
MeSH 42 D014523
ICD10 33 C68.0
ICD9CM 35 189.3

Summaries for Urethral Benign Neoplasm

Disease Ontology : 12 An urinary tract cancer that derives from the tissues of the urethra.

MalaCards based summary : Urethral Benign Neoplasm, also known as urethral neoplasms, is related to posterior urethra cancer and anterior urethra cancer. An important gene associated with Urethral Benign Neoplasm is FNDC3B (Fibronectin Type III Domain Containing 3B), and among its related pathways/superpathways is Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex. The drugs Goserelin and Dutasteride have been mentioned in the context of this disorder. Related phenotype is homeostasis/metabolism.

Related Diseases for Urethral Benign Neoplasm

Diseases in the Urethral Cancer family:

Urethral Benign Neoplasm

Diseases related to Urethral Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
id Related Disease Score Top Affiliating Genes
1 posterior urethra cancer 11.8
2 anterior urethra cancer 11.8
3 urethra transitional cell carcinoma 10.8
4 urethra adenocarcinoma 10.8
5 urethral cancer 10.8
6 urethra squamous cell carcinoma 10.8
7 conventional fibrosarcoma 10.2 CEACAM5 KLK3
8 prostate lymphoma 10.2 CEACAM5 KLK3
9 superficial urinary bladder cancer 10.2 AMACR KLK3
10 urinary tract obstruction 10.2 ALK CHGA
11 cervix endometriosis 10.2 AMACR UPK3A
12 klinefelter's syndrome 10.2 CHGA KLK3
13 colon signet ring adenocarcinoma 10.2 AMACR KLK3
14 perineural angioma 10.1 CEACAM5 CHGA
15 sphenoid sinus squamous cell carcinoma 10.1 CEACAM5 KLK3
16 vulva squamous cell carcinoma 10.1 CEACAM5 UPK3A
17 main bronchus cancer 10.1 CEACAM5 CHGA
18 parietal lobe neoplasm 10.1 CEACAM5 CHGA
19 myotonia congenita 10.1 CEACAM5 UPK3A
20 pigmented villonodular synovitis 10.1 CEACAM5 CHGA
21 uterine corpus endometrial stromal sarcoma 10.1 CEACAM5 UPK3A
22 cranial nerve disease 10.1 CEACAM5 KLK3
23 uterine corpus myxoid leiomyosarcoma 10.1 CEACAM5 CHGA
24 prostate small cell carcinoma 10.1 ATM KLK3 UPK3A
25 fuchs' heterochromic uveitis 10.1 AMACR KLK3 UPK3A
26 testicular trophoblastic tumor 10.1 CEACAM5 CHGA
27 rhinitis 10.1 AMACR KLK3 SMAD4
28 vagneur triolle ripert syndrome 10.1 CEACAM5 CHGA KLK3
29 vulvar keratoacanthoma-like carcinoma 10.1 CEACAM5 CHGA KLK3
30 respiratory syncytial virus infectious disease 10.0 ATM SMAD4
31 punctate epithelial keratoconjunctivitis 10.0 APP CEACAM5
32 submucosal invasive colon adenocarcinoma 10.0 CHGA SMAD4
33 prostate stromal sarcoma 10.0 CEACAM5 KLK3
34 adult medulloblastoma 10.0 AMACR CHGA KLK3
35 retinal telangiectasia 10.0 CEACAM5 CHGA SMAD4
36 benign shuddering attacks 10.0 CEACAM5 CHGA SMAD4
37 bone dysplasia azouz type 10.0 APP CHGA
38 bardet-biedl syndrome 10.0 AMACR CEACAM5 KLK3
39 splenic infarction 9.9 AMACR CHGA KLK3 UPK3A
40 vaginal villous adenoma 9.9 CEACAM5 CHGA
41 malignant pleural solitary fibrous tumor 9.9 ALK CEACAM5 CHGA KLK3
42 urethritis 9.6
43 prostatitis 9.6
44 prostatic adenoma 9.6
45 adenoma 9.6
46 renal pelvis carcinoma 8.8 ALK AMACR ANKRD28 APP ARID2 ATM
47 thymus gland disease 8.8 ALK AMACR ANKRD28 APP ARID2 ATM
48 iris spindle cell melanoma 8.5 ALK AMACR ANKRD28 APP ARID2 ATM

Comorbidity relations with Urethral Benign Neoplasm via Phenotypic Disease Network (PDN):


Acute Cystitis Hydronephrosis
Prostate Cancer Prostatic Hypertrophy
Urinary Bladder Cancer

Graphical network of the top 20 diseases related to Urethral Benign Neoplasm:



Diseases related to Urethral Benign Neoplasm

Symptoms & Phenotypes for Urethral Benign Neoplasm

MGI Mouse Phenotypes related to Urethral Benign Neoplasm:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.28 APP ARID2 ATM CHGA FNDC3B SMAD4

Drugs & Therapeutics for Urethral Benign Neoplasm

Drugs for Urethral Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Goserelin Approved Phase 4 65807-02-5 47725 5311128
2
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
3
Bethanechol Approved Phase 4 674-38-4 2370
4 Neurotransmitter Agents Phase 4
5 Steroid Synthesis Inhibitors Phase 4
6 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
7 Hormones Phase 4,Phase 3,Phase 2,Phase 1
8 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
10 5-alpha Reductase Inhibitors Phase 4
11 Cholinergic Agents Phase 4
12 Autonomic Agents Phase 4,Phase 2
13
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
14
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
15
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
16
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
17
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
18
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
19
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
21
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
22
Succinylcholine Approved Phase 3 306-40-1 5314
23
Bicalutamide Approved Phase 3 90357-06-5 56069 2375
24
Bevacizumab Approved, Investigational Phase 3 216974-75-3
25
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 54575, 6560146 143
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
27
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
28
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
29 Anesthetics Phase 3,Phase 2,Phase 1
30 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
31 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
32 Anti-Infective Agents Phase 3,Phase 2,Phase 1
33 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
34 Liver Extracts Phase 3,Phase 1
35 Antimetabolites Phase 3,Phase 2,Phase 1
36 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
37 Antiviral Agents Phase 3,Phase 2,Phase 1
38 pancreatic polypeptide Phase 3,Phase 1
39 Analgesics Phase 3,Phase 1,Phase 2
40 Alkylating Agents Phase 2, Phase 3
41 Mitomycins Phase 2, Phase 3
42 Adjuvants, Anesthesia Phase 3
43 Folic Acid Antagonists Phase 3,Phase 2
44 Narcotics Phase 3
45 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
46 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
47 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
48 Dermatologic Agents Phase 3,Phase 2,Phase 1
49 Analgesics, Opioid Phase 3
50 Anesthetics, General Phase 3

Interventional clinical trials:

(show top 50) (show all 163)
id Name Status NCT ID Phase
1 Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation Completed NCT00805701 Phase 4
2 Global Performance Evaluation of the AMS CONTINUUM™ Device Completed NCT01083199 Phase 4
3 TOMUS-Trial Of Mid-Urethral Slings Completed NCT00325039 Phase 4
4 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Not yet recruiting NCT02910596 Phase 4
5 Mixed Incontinence: Medical Or Surgical Approach? Terminated NCT00803270 Phase 4
6 Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging Unknown status NCT01004211 Phase 3
7 Mechanical Nerve Stimulation in the Treatment of Post Prostatectomy Incontinence Unknown status NCT01540656 Phase 3
8 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00003701 Phase 3
9 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3
10 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3
11 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3
12 Intravesical Adjuvant Electromotive Mitomycin-C Completed NCT01920269 Phase 2, Phase 3
13 Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial Completed NCT00247312 Phase 3
14 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
15 Tension-free Vaginal Tape (TVT) Versus Bulking Agent for the Treatment of Post Vulvectomy Urinary Incontinence Completed NCT01148290 Phase 3
16 Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer Recruiting NCT02968784 Phase 2, Phase 3
17 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3
18 Radiation Therapy With or Without Bicalutamide in Treating Patients With Stage II, Stage III, or Recurrent Prostate Cancer Active, not recruiting NCT00002874 Phase 3
19 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Active, not recruiting NCT02426125 Phase 3
20 ProACT Therapy for the Treatment of Stress Urinary Incontinence in Males Active, not recruiting NCT00277095 Phase 2, Phase 3
21 Fusion Guided Focal Laser Ablation of Prostate Cancer Not yet recruiting NCT02759744 Phase 3
22 Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract Unknown status NCT00006111 Phase 2
23 Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer Unknown status NCT01118039 Phase 2
24 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Unknown status NCT01191892 Phase 2
25 Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium Unknown status NCT01089088 Phase 2
26 Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer Unknown status NCT01126749 Phase 1, Phase 2
27 Dose Escalation to Dominant Intraprostatic Lesions (DIL) With MRI-TRUS Fusion High Dose Rate (HDR) Prostate Brachytherapy Unknown status NCT01909388 Phase 2
28 BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma Unknown status NCT02278978 Phase 2
29 TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium Completed NCT00077688 Phase 2
30 Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Completed NCT00002684 Phase 2
31 S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium Completed NCT00055835 Phase 2
32 Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment Completed NCT01031875 Phase 2
33 Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium Completed NCT00080795 Phase 2
34 S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium Completed NCT00045630 Phase 2
35 Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00053209 Phase 2
36 S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy Completed NCT00066612 Phase 2
37 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2
38 SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00006351 Phase 2
39 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2
40 Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function Completed NCT00005644 Phase 2
41 Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium Completed NCT00397488 Phase 2
42 Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer Completed NCT00004223 Phase 2
43 S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00014144 Phase 2
44 Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium Completed NCT01090466 Phase 1, Phase 2
45 Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer Completed NCT00003175 Phase 2
46 Arsenic Trioxide in Treating Patients With Urothelial Cancer Completed NCT00009867 Phase 2
47 A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer Completed NCT00661609 Phase 2
48 Pazopanib in Treating Patients With Metastatic Urothelial Cancer Completed NCT00471536 Phase 2
49 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function Completed NCT00478361 Phase 2
50 Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer Completed NCT00021099 Phase 2

Search NIH Clinical Center for Urethral Benign Neoplasm

Cochrane evidence based reviews: urethral neoplasms

Genetic Tests for Urethral Benign Neoplasm

Anatomical Context for Urethral Benign Neoplasm

Publications for Urethral Benign Neoplasm

Variations for Urethral Benign Neoplasm

Expression for Urethral Benign Neoplasm

Search GEO for disease gene expression data for Urethral Benign Neoplasm.

Pathways for Urethral Benign Neoplasm

Pathways related to Urethral Benign Neoplasm according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 9.97 ATM SMAD4

GO Terms for Urethral Benign Neoplasm

Biological processes related to Urethral Benign Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ovarian follicle development GO:0001541 9.16 ATM SMAD4
2 neuron apoptotic process GO:0051402 8.96 APP ATM
3 female gonad development GO:0008585 8.62 ATM SMAD4

Sources for Urethral Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....